SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue2376692,5363,061
Cost of Revenue----
Gross Profit2376692,5363,061
Operating Expenses
Research Development14,11520,84022,88123,701
Selling General and Administrative11,83214,24816,11518,662
Non Recurring----
Total Operating Expenses25,94735,08838,99642,363
Operating Income or Loss-25,710-34,419-36,460-39,302
Income from Continuing Operations
Total Other Income/Expenses Net-905-1,039-1,5632,626
Earnings Before Interest and Taxes-25,710-34,419-36,460-39,302
Interest Expense-1,154-1,396-1,721-939
Income Before Tax-26,615-35,458-38,023-36,676
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-26,615-35,458-38,023-36,676
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-26,615-35,458-38,023-36,676
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-26,615-35,458-38,023-36,676